Literature DB >> 12584565

Transgenic overexpression of IGF-II induces spontaneous lung tumors: a model for human lung adenocarcinoma.

Roger A Moorehead1, Otto H Sanchez, R Mitchell Baldwin, Rama Khokha.   

Abstract

Elevated levels of insulin-like growth factor (IGF)-II are associated with a poor prognosis in human pulmonary adenocarcinoma; however, a causal role for IGF-II in pulmonary adenocarcinoma has not been demonstrated. Here, we show that transgenic overexpression of IGF-II in lung epithelium induces lung tumors in 69% of mice older than 18 months of age. These tumors displayed morphological characteristics of human pulmonary adenocarcinoma such as their epithelial origin, tubulo-acinar architecture and expression of TTF-1, SP-B and proSP-C. Examination of signaling molecules downstream of the IGF-IR showed the activation of either the Erk1/Erk2 or p38 MAPK pathways, but not both, within the lung tumors. Notably, all lung tumors contained high levels of phosphorylated CREB, suggesting that both the Erk1/Erk2 and p38 MAPK pathways converged on this transcription factor. Moreover, IGF-II induced proliferation and CREB phosphorylation in human lung cancer cell lines, suggesting that IGF-II and CREB also contribute to the growth of human lung tumors. Thus, IGF-II is an important genetic factor in the development of lung tumorigenesis, in which activation of CREB is a ubiquitous event. The MMTV-IGF-II transgenic mice provide a critical model for elucidating the role of IGF-II in this fatal human disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12584565     DOI: 10.1038/sj.onc.1206188

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  29 in total

Review 1.  The endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?

Authors:  Martin McLaughlin; Koen Vandenbroeck
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

2.  Development of a Grp94 inhibitor.

Authors:  Adam S Duerfeldt; Laura B Peterson; Jason C Maynard; Chun Leung Ng; Davide Eletto; Olga Ostrovsky; Heather E Shinogle; David S Moore; Yair Argon; Christopher V Nicchitta; Brian S J Blagg
Journal:  J Am Chem Soc       Date:  2012-05-29       Impact factor: 15.419

3.  Effects of alpha-interferon on insulin-like growth factor-I, insulin-like growth factor-II and insulin-like growth factor binding protein-3 secretion by a human lung cancer cell line in vitro.

Authors:  P Del Monte; C Laurino; M Arvigo; C Palermo; F Minuto; A Barreca
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

4.  Type I insulin-like growth factor receptor induces pulmonary tumorigenesis.

Authors:  Nicolle M Linnerth; Megan D Siwicky; Craig I Campbell; Katrina L M Watson; James J Petrik; Jeffrey A Whitsett; Roger A Moorehead
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

5.  Development of targeted therapy for a broad spectrum of solid tumors mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P4 and IGF2-P3 regulatory sequences.

Authors:  Doron Amit; Sagi Tamir; Abraham Hochberg
Journal:  Int J Clin Exp Med       Date:  2013-01-26

6.  Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review.

Authors:  Ming Yin; Xiaoxiang Guan; Zhongxin Liao; Qingyi Wei
Journal:  Am J Transl Res       Date:  2009-01-30       Impact factor: 4.060

Review 7.  Obesity and cancer--mechanisms underlying tumour progression and recurrence.

Authors:  Jiyoung Park; Thomas S Morley; Min Kim; Deborah J Clegg; Philipp E Scherer
Journal:  Nat Rev Endocrinol       Date:  2014-06-17       Impact factor: 43.330

8.  Growth suppression of lung cancer cells by targeting cyclic AMP response element-binding protein.

Authors:  Sita Aggarwal; Seung-Wook Kim; Seung-Hee Ryu; Wen-Cheng Chung; Ja Seok Koo
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

9.  Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin.

Authors:  Celia A Kanashiro; Andrew V Schally; Kate Groot; Patricia Armatis; Andrea L F Bernardino; Jozsef L Varga
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-05       Impact factor: 11.205

10.  Cyclic AMP response element-binding protein overexpression: a feature associated with negative prognosis in never smokers with non-small cell lung cancer.

Authors:  Hye-Sook Seo; Diane D Liu; B Nebiyou Bekele; Mi-Kyoung Kim; Katherine Pisters; Scott M Lippman; Ignacio I Wistuba; Ja Seok Koo
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.